Tercica (TRCA) Reports Q2 loss of $0.22
More News related to TRCA
- Tercica (TRCA) Reports Q2 loss of $0.22
- Caxton Associates Accumulates 5.1% Stake in Tercica (TRCA)
- Tercica (TRCA) Reports Results from Increlex(R) IGFD Patient Registry
- Unusual 11 Mid-Day Movers 6/5: TRCA, AERG, SQNM, HOTT Higher; REGN, IDT, WBS, BTH Lower
- Notable Mergers and Acquisitions of the Day 6/5 (VZ, TRCA, BGP)
More News related to Earnings
- Coca-Cola (KO) Q4 Profits Surge, Helped by Emerging Markets
- Versar (VSR) Swings to Q2 Loss of $0.03
- Martin Marietta Materials (MLM) Swings to Q4 Loss of $0.07
- RG Barry (DFZ) Posts Q2 EPS of $0.74, Beats by 9c
- Banco Popular (BPOP) Posts Q4 Loss of $0.33, Lower from Q309
Tercica Inc. (Nasdaq: TRCA) reports a Q2 loss of $0.22, versus the consensus of a $0.31 loss. Revenues came in at $6.2 million, versus the consensus of $7.45 million.
Tercica, Inc., a biopharmaceutical company, engages in the development and marketing of endocrine products.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
